7 reports of this reaction
3.1% of all DEXTROMETHORPHAN HBR AND GUAIFENESIN reports
#2 most reported adverse reaction
DISEASE RECURRENCE is the #2 most commonly reported adverse reaction for DEXTROMETHORPHAN HBR AND GUAIFENESIN, manufactured by Cardinal Health 110, LLC. DBA Leader. There are 7 FDA adverse event reports linking DEXTROMETHORPHAN HBR AND GUAIFENESIN to DISEASE RECURRENCE. This represents approximately 3.1% of all 224 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN HBR AND GUAIFENESIN who experience disease recurrence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE RECURRENCE is moderately reported among DEXTROMETHORPHAN HBR AND GUAIFENESIN users, representing a notable but not dominant share of adverse events.
In addition to disease recurrence, the following adverse reactions have been reported for DEXTROMETHORPHAN HBR AND GUAIFENESIN:
The following drugs have also been linked to disease recurrence in FDA adverse event reports:
DISEASE RECURRENCE has been reported as an adverse event in 7 FDA reports for DEXTROMETHORPHAN HBR AND GUAIFENESIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE RECURRENCE accounts for approximately 3.1% of all adverse event reports for DEXTROMETHORPHAN HBR AND GUAIFENESIN, making it one of the most commonly reported side effect.
If you experience disease recurrence while taking DEXTROMETHORPHAN HBR AND GUAIFENESIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.